JP2023546713A - Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 - Google Patents

Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 Download PDF

Info

Publication number
JP2023546713A
JP2023546713A JP2023524833A JP2023524833A JP2023546713A JP 2023546713 A JP2023546713 A JP 2023546713A JP 2023524833 A JP2023524833 A JP 2023524833A JP 2023524833 A JP2023524833 A JP 2023524833A JP 2023546713 A JP2023546713 A JP 2023546713A
Authority
JP
Japan
Prior art keywords
btla
seq
binding agent
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546713A5 (enExample
Inventor
エドワード ダール、マーティン
パームリー、スティーブン
ケーリー、マリリン
ダ シルヴァ コレイア、ジャン
ショウ、モレナ
Original Assignee
アナプティスバイオ インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アナプティスバイオ インコーポレイティッド filed Critical アナプティスバイオ インコーポレイティッド
Publication of JP2023546713A publication Critical patent/JP2023546713A/ja
Publication of JP2023546713A5 publication Critical patent/JP2023546713A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023524833A 2020-10-23 2021-10-22 Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法 Pending JP2023546713A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105067P 2020-10-23 2020-10-23
US63/105,067 2020-10-23
US202163192984P 2021-05-25 2021-05-25
US63/192,984 2021-05-25
PCT/US2021/056289 WO2022087441A2 (en) 2020-10-23 2021-10-22 B and t lymphocyte attenuator (btla) modulators and method of using same

Publications (2)

Publication Number Publication Date
JP2023546713A true JP2023546713A (ja) 2023-11-07
JP2023546713A5 JP2023546713A5 (enExample) 2024-10-25

Family

ID=78695822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524833A Pending JP2023546713A (ja) 2020-10-23 2021-10-22 Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法

Country Status (9)

Country Link
US (1) US20230391872A1 (enExample)
EP (1) EP4232480A2 (enExample)
JP (1) JP2023546713A (enExample)
KR (1) KR20230096024A (enExample)
AU (1) AU2021365611A1 (enExample)
CA (1) CA3196493A1 (enExample)
IL (1) IL302135A (enExample)
MX (1) MX2023004633A (enExample)
WO (1) WO2022087441A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023259623A1 (en) * 2022-04-27 2024-11-21 First Tracks Biotherapeutics, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500715A (ja) * 2009-07-31 2013-01-10 メダレックス インコーポレーティッド Ｂｔｌａに対する完全ヒト抗体
WO2020128446A2 (en) * 2018-12-17 2020-06-25 Oxford University Innovation Limited Btla antibodies
JP2020518288A (ja) * 2017-05-19 2020-06-25 イーライ リリー アンド カンパニー Ｂｔｌａアゴニスト抗体およびその使用
WO2020205849A1 (en) * 2019-04-01 2020-10-08 Lakepharma, Inc. Btla-binding (cd272) antibodies for modulating immune response and treating disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2007001459A2 (en) * 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
AU2023259623A1 (en) * 2022-04-27 2024-11-21 First Tracks Biotherapeutics, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500715A (ja) * 2009-07-31 2013-01-10 メダレックス インコーポレーティッド Ｂｔｌａに対する完全ヒト抗体
JP2020518288A (ja) * 2017-05-19 2020-06-25 イーライ リリー アンド カンパニー Ｂｔｌａアゴニスト抗体およびその使用
WO2020128446A2 (en) * 2018-12-17 2020-06-25 Oxford University Innovation Limited Btla antibodies
WO2020205849A1 (en) * 2019-04-01 2020-10-08 Lakepharma, Inc. Btla-binding (cd272) antibodies for modulating immune response and treating disease

Also Published As

Publication number Publication date
WO2022087441A3 (en) 2022-08-25
CA3196493A1 (en) 2022-04-28
AU2021365611A9 (en) 2025-03-13
EP4232480A2 (en) 2023-08-30
AU2021365611A1 (en) 2023-06-08
KR20230096024A (ko) 2023-06-29
US20230391872A1 (en) 2023-12-07
IL302135A (en) 2023-06-01
WO2022087441A2 (en) 2022-04-28
MX2023004633A (es) 2023-05-12

Similar Documents

Publication Publication Date Title
JP7212098B2 (ja) インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
JP6882702B2 (ja) インターロイキン−３３（ｉｌ−３３）に対する抗体
JP7490679B2 (ja) Ｐｄ－１アゴニストおよびそれを使用する方法
US20250282872A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
US20260062488A1 (en) Anti-alpha-4-beta-7 antibodies
US20230391872A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
JP2025537224A (ja) Ｃｄ１２２結合剤およびその使用方法
EA053216B1 (ru) Модуляторы в- и т-лимфоцитарных аттенюаторов (btla) и способ их применения
CN116685603A (zh) B和t淋巴细胞衰减因子（btla）调节剂及其使用方法
HK40093375A (en) B and t lymphocyte attenuator (btla) modulators and method of using same
EA050223B1 (ru) Агонист pd-1 и способ его применения
HK40086847A (en) Antibodies directed against interleukin 36 receptor (il-36r)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230703

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260512